v3.23.2
Product Revenue, Net
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Product Revenue, Net Product Revenue, Net
To date, the Company’s only source of product revenue has been from the U.S. sales of Auryxia. Total net product revenue was $176.9 million, $140.3 million, and $128.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2020, 2021 and 2022 (in thousands):
 Chargebacks
and
Discounts		Rebates, Fees
and other
Deductions		Product ReturnsTotal
Balance at December 31, 2019$634 $31,404 $7,498 $39,536 
Provisions related to sales in current year10,613 150,376 9,672 170,661 
Adjustments related to prior year sales— 377 (867)$(490)
Credits/payments made(10,495)(140,489)(6,691)$(157,675)
Balance at December 31, 2020752 41,668 9,612 52,032 
Current provisions related to sales in current year11,579 132,016 6,499 150,094 
Adjustments related to prior year sales(1)(1,790)— (1,791)
Credits/payments made(11,282)(144,794)(6,047)(162,123)
Balance at December 31, 2021$1,048 $27,100 $10,064 $38,212 
Current provisions related to sales in current year11,411 90,264 5,828 107,503 
Adjustments related to prior year sales(9)401 — 392 
Credits/payments made(11,191)(87,722)(4,969)(103,882)
Balance at December 31, 2022$1,259 $30,043 $10,923 $42,225 
 
Chargebacks, discounts and estimated product returns are recorded as a direct reduction of revenue on the consolidated statement of operations and comprehensive income (loss). Chargebacks are recorded as a reduction to accounts receivable on the consolidated balance sheets. Rebates, discounts, fees and other deductions as well as distribution-related fees and other sales-related deductions are recorded as a reduction in revenue on the consolidated statement of operations with a corresponding increase to accrued liabilities or accounts payable on the consolidated balance sheets. Estimated product returns for current product sales are recorded as other long-term liabilities in the unaudited condensed consolidated balance sheet.
 
Accounts receivable, net related to product sales was approximately $37.3 million and $25.3 million as of December 31, 2022 and 2021, respectively.